期刊文献+

盐酸伊立替康新型载体材料微粒给药系统的研究 被引量:2

New Carrier Materials for Particles Drug Delivery System of Irinotecan Hydrochloride
原文传递
导出
摘要 目的制备盐酸伊立替康胶束给药系统,降低其毒副作用,提高治疗效果。方法首先将盐酸伊立替康制备成磷脂复合物,提高其脂溶性;以合成的聚己内酯-聚乙二醇共聚物作为载体材料,将盐酸伊立替康磷脂复合物包裹其中,制备聚合物胶束给药系统。单因素结合正交试验,筛选制备盐酸伊立替康胶束给药系统的最佳处方和制备工艺。结果盐酸伊立替康磷脂复合物与原药相比脂溶性显著增加;制得的盐酸伊立替康胶束呈球形,粒径分布较均匀,包封率平均为61.32%,载药量平均为2.88%。结论通过该方法制得的盐酸伊立替康胶束粒径较小、质量可控,有望提高靶向部位药物浓度。 OBJECTIVE To prepare micelle drug delivery system of irinotecan hydrochloride, which could reduce its side effects and improve the therapeutic effects.METHODS Firstly, the irinotecan hydrochloride was prepared as phospholipid compound to improve the lipophilicity. The synthesized polycaprolactone-polyethylene glycol copolymer was used as carrier material, then the phospholipid complex of irinotecan hydrochloride was wrapped to prepare a polymer micelle drug delivery system. The optimum prescription and preparation process of micelle drug delivery system of irinotecan hydrochloride were screened by the method of single factor combined with orthogonal test.RESULTS The liposoluble of phospholipid compound of irinotecan hydrochloride was obviously increased compared with active compound. The irinotecan hydrochloride micelle was spherical and its particle size distribution was uniform. The average entrapment efficiency was 61.32%, and the average drug loading was 2.88%.CONCLUSION Through this method, the particle size of irinotecan hydrochloride is small and the quality is controllable, and it is hopeful to increase the drug concentration at the target site.
作者 邓盛齐 蒋芳 任静 郑林 王玲玲 李晓琴 DENG Sheng-qi;JIANG Fang;REN Jing;ZHENG Lin;WANG Ling-ling;LI Xiao-qin(Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu 610052, China;Chongqing Motorcycle & Automobile Intellectual Property Information Center, Chongqing 401147, China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2018年第13期1093-1097,共5页 Chinese Pharmaceutical Journal
基金 四川省科技计划应用基础计划资助(2015JY0031)
关键词 盐酸伊立替康 磷脂复合物 两亲性嵌段共聚物 胶束给药系统 irinotecan hydrochloride phospholipid compound amphiphilic block copolymer micellar drug delivery system
  • 相关文献

参考文献1

二级参考文献10

  • 1司徒镇强,吴军正.细胞培养[M].西安:世界图书出版公司,2005.266 被引量:8
  • 2Saikawa Y, Kubota T, Furukawa T, et al. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer [ J ]. Jpn J Cancer Res, 1994,85 ( 7 ) :762 - 765. 被引量:1
  • 3Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [ J ]. Pharmacal Rev, 2006,58 ( 3 ) :621 - 681. 被引量:1
  • 4Ashley AC, Sargent DJ, Alberts SR, et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cance [J]. Cancer, 2007,110(3) :670-677. 被引量:1
  • 5Aschele C, Debemardis D, Casazza S, et al. Immunohistochemical quantitation of thymidylate synthase expression in calorectal cancer matastases predicts for clinical outcome to fluorouracilbased chemotherapy[J]. J Clin Oncol, 1999, 17 (6) :1760 - 1770. 被引量:1
  • 6Ladner RD, Lynch FJ, Groshen S, et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer[J]. Cancer Res, 2000, 60 (13):3493-3503. 被引量:1
  • 7Smorenburg CH, Peters GJ, van Groeningen C J, et al. Phase Ⅱ study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovofin or oxaliplatin and ifinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase [ J ]. Ann Oncol, 2006,17 ( 1 ) :35 - 42. 被引量:1
  • 8Ciaparrone M, Quifino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil[ J ]. Oncology,2006,70 ( 5 ) : 366 - 377. 被引量:1
  • 9Falcone A, Ricci S, Brunetti I , et al. Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan ( FOL- FOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncalogico Nord Ovest[J]. J Clin Oncol, 2007,25(13) :1670 - 1676. 被引量:1
  • 10Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line[J]. J Clin Oncol, 2005,23(36) : 9441 - 9442. 被引量:1

共引文献6

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部